What is the maximum recommended dose of Lyrica (pregabalin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Recommended Dose of Pregabalin (Lyrica)

The maximum recommended dose of pregabalin (Lyrica) is 600 mg per day, typically divided into 2-3 doses. 1, 2

Dosing Guidelines by Indication

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

  • Starting dose: 50 mg three times daily (150 mg/day)
  • Maximum recommended dose: 100 mg three times daily (300 mg/day) 2
  • Higher doses (600 mg/day) do not confer additional benefits and are associated with more adverse effects 2

Postherpetic Neuralgia

  • Starting dose: 75 mg twice daily or 50 mg three times daily (150 mg/day)
  • Initial maximum: 300 mg/day (can be reached within 1 week)
  • Extended maximum: Up to 600 mg/day (300 mg twice daily or 200 mg three times daily) for patients who:
    • Do not experience sufficient pain relief after 2-4 weeks at 300 mg/day
    • Can tolerate the medication
    • Have ongoing pain 2

Fibromyalgia

  • Starting dose: 75 mg twice daily (150 mg/day)
  • Recommended dose range: 300-450 mg/day
  • Maximum dose: 450 mg/day (225 mg twice daily) 2
  • Although studied at 600 mg/day, there is no evidence of additional benefit at this dose, and it was less well tolerated 2

Adjunctive Therapy for Partial-Onset Seizures

  • Adults: Starting at 150 mg/day with maximum of 600 mg/day 2
  • Pediatric patients ≥30 kg: Maximum 10 mg/kg/day (not to exceed 600 mg/day) 2
  • Pediatric patients <30 kg: Maximum 14 mg/kg/day 2

Dosing Considerations

Renal Impairment

Pregabalin is eliminated primarily by renal excretion (98%), requiring dose adjustments in patients with reduced renal function 2, 3:

Creatinine Clearance (mL/min) Total Daily Dose Range (mg/day) Dose Regimen
≥60 900-3600 300-1200 mg TID
>30-59 400-1400 200-700 mg BID
>15-29 200-700 200-700 mg QD
≤15 100-300 100-300 mg QD

Titration Recommendations

  • Begin with lower doses and gradually increase to minimize adverse effects 1
  • For most indications, allow 1 week between dose increases 2
  • When discontinuing, taper gradually over a minimum of 1 week to avoid withdrawal symptoms 2

Efficacy and Dose-Response Relationship

The efficacy of pregabalin is dose-dependent, but so are adverse effects:

  • In postherpetic neuralgia, significant pain reduction is seen even at 150 mg/day 4
  • In diabetic neuropathy, 300 mg/day is typically required for significant pain reduction 3, 4
  • For mixed neuropathic pain conditions, 600 mg/day shows better efficacy than lower doses 4
  • Doses above 300 mg/day are associated with higher rates of adverse effects without consistently better efficacy 1, 2

Common Adverse Effects

Adverse effects are dose-dependent and include:

  • Dizziness: 13-46% (increasing with dose) 4, 5
  • Somnolence: 11-32% (increasing with dose) 4, 5
  • Peripheral edema: 10.4% 3

These side effects are generally mild to moderate and can often be managed with dose reduction rather than discontinuation 3.

Important Considerations

  • Pregabalin has a high oral bioavailability (approximately 90%) 6
  • It can be taken with or without food 2
  • Plasma half-life is about 6 hours 6
  • While rare, some patients may use pregabalin above recommended dosages (9.6% used >600 mg/day for 6+ months in one study) 7
  • Male gender and concurrent use of antipsychotics or benzodiazepines are associated with higher risk of using above-recommended dosages 7

Pregabalin's maximum dose of 600 mg/day should be reserved for specific indications and patients who have not achieved adequate pain relief at lower doses, while carefully monitoring for adverse effects.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Pregabalin--profile of efficacy and tolerability in neuropathic pain].

Drugs of today (Barcelona, Spain : 1998), 2009

Research

Pregabalin for neuropathic pain in adults.

The Cochrane database of systematic reviews, 2019

Research

Pregabalin for acute and chronic pain in adults.

The Cochrane database of systematic reviews, 2009

Research

Pregabalin: a new agent for the treatment of neuropathic pain.

Drugs of today (Barcelona, Spain : 1998), 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.